# Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

> **NCT03062319** · PHASE4 · TERMINATED · sponsor: **National Hospital Organization Osaka National Hospital** · enrollment: 321 (actual)

## Conditions studied

- Ischemic Stroke
- Atrial Fibrillation
- Atherothrombosis

## Interventions

- **DRUG:** Oral Anticoagulant
- **DRUG:** Antiplatelet Drug

## Key facts

- **NCT ID:** NCT03062319
- **Lead sponsor:** National Hospital Organization Osaka National Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-06
- **Primary completion:** 2023-07-18
- **Final completion:** 2023-07-18
- **Target enrollment:** 321 (ACTUAL)
- **Why stopped:** The trial was terminated at the planned interim analysis for futility on July 18, 2023.
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062319, "Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03062319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*